Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Barber

Gastroenterology Grand Rapids, MI Medical Doctor

NPI 1417177866 CMS profile 336279

4100 Lake Dr Se Ste 205, Grand Rapids, MI 49546

Open in the dashboard

General payments

$108,613

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Barber of Grand Rapids, MI is reported in the CMS Open Payments database as having received $108,613 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,947 10
2024 General $26,374 37
2023 General $11,423 17
2022 General $26,649 45
2021 General $33,272 29
2020 General $3,729 14
2019 General $4,219 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Barber
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jeremy Barber were reported at $2,947. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jeremy Barber Gastroenterology median Middle half National median
2019 $4,219 $417 $126–$1,100 $163
2020 $3,729 $224 $74–$624 $114
2021 $33,272 $352 $106–$1,054 $132
2022 $26,649 $448 $129–$1,270 $149
2023 $11,423 $533 $150–$1,390 $160
2024 $26,374 $605 $160–$1,606 $164
2025 $2,947 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $74,503 110 payments
  2. PENTAX of America, Inc. $19,041 36 payments
  3. Siemens Medical Solutions USA, Inc. $7,380 2 payments
  4. CSA Medical, Inc $3,226 2 payments
  5. US Endoscopy $3,000 3 payments
  6. Ambu Inc. $514 3 payments
  7. Steris Corporation $332 2 payments
  8. Olympus America Inc. $143 2 payments
  9. Viatris Specialty LLC $122 1 payment
  10. Apollo Endosurgery US Inc $113 1 payment
  11. Other $238 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,071 50 payments
  2. Consulting Fee $32,675 14 payments
  3. Food and Beverage $9,034 88 payments
  4. Travel and Lodging $5,833 17 payments
Products named General payments · program years 2019–2025
  1. EXALT Model D Exalt_Endo $18,619 24 payments
  2. Aloka Arietta 850 $14,571 14 payments
  3. EXALT Model D EXALT Model D_ENDO $10,328 16 payments
  4. General Therapies $10,075 7 payments
  5. Cios Spin $7,380 2 payments
  6. EXALT BX 2 $6,237 3 payments
  7. SpyBite $5,100 2 payments
  8. TruFreeze $3,332 5 payments
  9. EXALT $2,975 2 payments
  10. EXALT BX 6 $2,763 1 payment
  11. Other $13,683 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

671

Median for Gastroenterology: 569

Drug cost

$390,137

Median for Gastroenterology: $104,976

Branded share of claims

39.5%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 61 $374,304
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 150 $3,790
Pantoprazole Sodium Generic 269 $3,740
Sucralfate Generic 33 $2,992
Ursodiol Generic 12 $2,799
Omeprazole Generic 53 $912
Esomeprazole Magnesium Generic 24 $676
Lidocaine Hcl Viscous Lidocaine Hcl Brand 18 $476
Famotidine Generic 15 $193
Ondansetron Odt Ondansetron Brand 11 $157

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$70,754

Medicare's payments for the services billed

Medicare patients

241

Average age 74

Services billed

495

123 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 39%
Chronic kidney disease 37%
Depression 34%
COPD 32%
Ischemic heart disease 30%
Heart failure 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record